Development of therapeutic strategy against TBI based on hydrogen sulfide
Development of therapeutic strategy against TBI based on hydrogen sulfide
批准号:
9175254
负责人:
Nilkantha Sen
金额:
$33.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2021-03-31
关键词:
AffectAftercareAstrocytesAttenuatedBoxingBrain-Derived Neurotrophic FactorCREB1 geneCell DeathCell membraneCell physiologyCerebral EdemaCerebrospinal FluidCessation of lifeClinicalClinical TrialsComplexConfocal MicroscopyCystathionine beta-SynthaseCysteineDataDevelopmentEdemaEventFunctional disorderGoalsHumanHydrogen SulfideImpaired cognitionImpairmentInflammationInflammatoryInflammatory ResponseInjuryMeasuresMediatingMemory impairmentMessenger RNAModelingMonitorMorbidity - disease rateMusNatureNeurologicNeurological outcomeNeuronsOutcomePathologyPathway interactionsPatientsPhosphorylationPreventionProcessProtective AgentsProtein KinaseProteinsProto-Oncogene Proteins c-aktRecovery of FunctionSamplingSulfhydryl CompoundsSurvivorsTestingTherapeuticTherapeutic AgentsTranscriptional ActivationTraumatic Brain InjuryTraumatic Brain Injury recoveryVertebral columnWalkingWestern Blottingbasecell typecytokinedensitydisabilitydrug testingfunctional outcomesimprovedin vivoinhibitor/antagonistinnovationmorris water mazemortalitymutantneurobehavioralneurobehavioral testneurogenesisneuroprotectionnovelnovel therapeutic interventionoutcome predictionoverexpressionpreventsecondary outcomesmall moleculesulfhydrationtherapeutic development
中文摘要
创伤性脑损伤(TBI)是发病率和死亡率的主要原因,影响超过170万人
英文摘要
Traumatic Brain Injury (TBI) is a major cause of morbidity and mortality and it affects more than 1.7 million
people in the USA per year. TBI is multifactorial in nature however cerebral edema with robust inflammatory
responses remains the most significant predictor of outcome of TBI. A critical barrier to progress in treating TBI
is the absence of effective neuro-protective therapeutics. Most of the neuro-protective drugs tested in mice
have failed in human clinical trials because they target a single factor, which mediates secondary injury in TBI.
Our compelling preliminary data suggests that inactivation of a key survival protein Akt, by a gasotransmitter,
hydrogen sulfide is responsible for outcomes associated with TBI. TBI-induced increase in hydrogen sulfide
causes sulfhydration of Akt (Akt-SSH) which leads to inactivation of its catalytic activity and stimulates several
secondary outcomes that leads to neurobehavioral impairment following TBI. Based on our data the central
hypothesis is that in addition to neuroprotection, inhibition of Akt-sulfhydration stimulates neurogenesis and
improves neurological outcomes to promote functional recovery after TBI. To test our hypothesis in Specific
Aim 1 we will determine how TBI induced Akt-sulfhydration affects Akt activity. In specific Aim 2 we will
determine whether prevention of Akt-sulfhydration improves TBI-pathology, and in specific aim 3 we will study
how Akt-sulfhydration impacts neurogenesis, spine density and cognitive impairment following TBI. Therefore,
investigating the potential of inhibition of Akt-sulfhydration in TBI is a novel proposal with clinical implications
and translational value. Successful accomplishment of this project will show the feasibility of a new treatment
paradigm for TBI, introducing the concept that reduction in the level of Akt-sulfhydration accelerates
neuroprotection, neurorepair and reduces disabilities in TBI survivors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of therapeutic strategy against TBI based on hydrogen sulfide
-
批准号:9903469
-
项目类别:
-
资助金额:$34.23万
-
财政年份:2017
-
负责人:Nilkantha Sen
-
依托单位:
Molecular Mechanisms underlying vision impairment after TBI
-
批准号:9420719
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2017
-
负责人:Nilkantha Sen
-
依托单位:
海外基金